| pubmed-article:10938594 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C0334438 | lld:lifeskim |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:10938594 | lifeskim:mentions | umls-concept:C0075134 | lld:lifeskim |
| pubmed-article:10938594 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10938594 | pubmed:dateCreated | 2000-11-24 | lld:pubmed |
| pubmed-article:10938594 | pubmed:abstractText | Twenty-three patients with HBe antigen-positive chronic hepatitis B were treated with capitalite first letters Maruyama (SSM). HBe antigen turned negative in 15 patients. The levels of various cytokines in pre- and post-treatment frozen serum samples from six patients whose HBe antigen turned negative and from five whose HBe antigen did not were examined. Reduction of serum interleukin (IL) -10 level to below 20 pg/ml was observed after SSM treatment in four of the six patients whose HBe antigen turned negative. SSM was found to stimulate the production of interferon (IFN) -gamma in peripheral blood cells from two healthy volunteers. This stimulatory effect was confirmed in 12 out of 24 healthy volunteers. SSM augmented the production of IFN-gamma in eight out of 10 patients with chronic hepatitis B and nine of 10 with hepatitis C. These results demonstrate for the first time that SSM stimulates the production of IFN-gamma in human peripheral blood cells and also suggest that treatment of HBe antigen-positive chronic hepatitis B patients with SSM leads to the clearance of HBe antigen and normalization of serum aspartate aminotransferase levels through inhibition of IL-10 and stimulation of IFN-gamma. | lld:pubmed |
| pubmed-article:10938594 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10938594 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10938594 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10938594 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10938594 | pubmed:issn | 1345-4676 | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:OkumuraHH | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:SatomuraKK | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:AramakiTT | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:FujisakiSS | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:YimNN | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:SekiyamaTT | lld:pubmed |
| pubmed-article:10938594 | pubmed:author | pubmed-author:OhmotoYY | lld:pubmed |
| pubmed-article:10938594 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10938594 | pubmed:volume | 67 | lld:pubmed |
| pubmed-article:10938594 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10938594 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10938594 | pubmed:pagination | 261-6 | lld:pubmed |
| pubmed-article:10938594 | pubmed:dateRevised | 2011-8-1 | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:meshHeading | pubmed-meshheading:10938594... | lld:pubmed |
| pubmed-article:10938594 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10938594 | pubmed:articleTitle | Effects of SSM (specific substance maruyama) on HBe antigen-positive chronic hepatitis B -clinical efficacy and modulation of cytokines. | lld:pubmed |
| pubmed-article:10938594 | pubmed:affiliation | The First Department of Internal Medicine, Nippon Medical School. | lld:pubmed |
| pubmed-article:10938594 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10938594 | pubmed:publicationType | Clinical Trial | lld:pubmed |
